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Abstract
Purpose: This study investigates whether 4π noncoplanar radiation therapy can spare the co-
chleae and consequently potentially improve hearing preservation in patients with acoustic neuroma
who are treated with radiation therapy.
Methods and materials: Clinical radiation therapy plans for 30 patients with acoustic neuroma
were included (14 stereotactic radiation surgery [SRS], 6 stereotactic radiation therapy [SRT], and
10 intensity modulated radiation therapy [IMRT]). The 4π plans were created for each patient with
20 optimal beams selected using a greedy column generation method and subsequently recalcu-
lated in Eclipse for comparison. Organ-at-risk (OAR) doses, homogeneity index, conformity, and
tumor control probability (TCP) were compared. Normal tissue complication probability (NTCP)
was calculated for sensorineural hearing loss (SNHL) at 3 and 5 years posttreatment. The dose for
each plan was then escalated to achieve 99.5% TCP.
Results: 4π significantly reduced the mean dose to both cochleae by 2.0 Gy (32%) for SRS, 3.2 Gy
(29%) for SRT, and 10.0 Gy (32%) for IMRT. The maximum dose to both cochleae was also reduced
with 4π by 1.6 Gy (20%), 2.2 Gy (15%), and 7.1 Gy (18%) for SRS, SRT, and IMRT plans, re-
spectively. The reductions in mean/maximum brainstem dose with 4π were also statistically significant.
Mean doses to other OARs were reduced by 19% to 56% on average. 4π plans had a similar CN
and TCP, with a significantly higher average homogeneity index (0.93 vs 0.92) and significantly
lower average NTCP for SNHL at both 3 years (30.8% vs 40.8%) and 5 years (43.3% vs 61.7%).
An average dose escalation of approximately 116% of the prescription dose achieved 99.5% TCP,
which resulted in 32.6% and 43.4% NTCP for SNHL at 3 years and 46.4% and 64.7% at 5 years
for 4π and clinical plans, respectively.
Conclusions: Compared with clinical planning methods, optimized 4π radiation therapy enables
statistically significant sparing of the cochleae in acoustic neuroma treatment as well as lowering
of other OAR doses, potentially reducing the risk of hearing loss.
© 2018 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Introduction
Acoustic neuroma, also known as vestibular schwannoma,
is a benign brain tumor arising from the eighth cervical
nerve. There are 2000 to 3000 new cases of benign acous-
tic neuroma diagnosed in the United States each year,
approximately 25% of which are treated with radiation
therapy.1 Due to its benign nature, the prognosis for pa-
tients with acoustic neuroma is typically very good, and
with proper surveillance and treatment, no decrease in lifes-
pan is expected. Therefore, the long-term posttreatment
toxicity must be heavily weighted for these patients. Al-
though the complication rates are much lower than with
surgery,2-4 some patients experience radiation-induced side
effects after treatment. Up to 40% of patients may expe-
rience middle ear side effects such as otitis media during
treatment,5 which can cause tinnitus, dizziness, and pain.
Almost half of patients may also experience some degree
of sensorineural hearing loss (SNHL), which continues to
worsen for years after treatment.6-12
There is evidence suggesting a correlation between the
dose to the cochlea and the degree of hearing loss ob-
served after radiation therapy for tumors in the head and
neck region.13-17 For patients with acoustic neuroma who
were treated with fractionated stereotactic radiation therapy,
a study by Thomas et al showed that the minimum and
maximum cochlear doses, as well as the percentage of the
cochlea receiving 50%, 80%, and 90% of the prescription
dose, were all strongly predictive of subsequent hearing
deterioration.18 For stereotactic radiation surgery (SRS), sig-
nificantly better hearing preservation was observed by Kano
et al when the dose to the central cochlea was kept below
4.2 Gy.19 Timmer et al also demonstrated a correlation
between the maximum cochlear dose and the extent of
hearing loss in patients with acoustic neuroma who were
treated with Gamma Knife radiation surgery.20
In addition to hearing loss, many patients with acous-
tic neuroma experience cranial neuropathy after radiation
therapy. In a study of 149 cases of acoustic neuroma ra-
diosurgery, Foote et al found that the maximum dose to the
brainstem was the most significant predictor of the inci-
dence of facial, trigeminal, or any other type of neuropathy
after treatment.21 Therefore, the sparing of dose to the brain-
stem must also be a high priority for these patients.
However, adequate radiation doses must still be deliv-
ered to achieve long-term tumor control. A large Gamma
Knife patient cohort established that a median single-
fractional dose of 13 Gy to the tumor margin (50% isodose)
is necessary for local control.8 This dose prescription typi-
cally results in maximum doses of 26 Gy for Gamma Knife
plans, which may not always be safely deliverable,22 par-
ticularly for larger tumors. Although 12 to 13 Gy is also
the standard prescription dose for linac-based single-
fraction acoustic neuroma treatment, these plans follow
different prescription conventions (typically 100% of the
prescription dose to 95%-100% of the target volume) and
result in more homogeneous dose distributions with lower
maximum doses.
Therefore, to reduce the risk of hearing loss and other
normal tissue complications after treatment while also de-
livering enough dose for maximal tumor control, highly
conformal dose distributions are needed that can better spare
the surrounding normal tissue. The dosimetry of Gamma
Knife has been compared with conformal and dynamic arcs
using linacs for acoustic neuroma treatment.23 Although the
Gamma Knife dose was slightly more conformal (by 2%),
the maximal dose was also much higher. This may help local
control but can increase the risk of hearing loss and other
neurologic side effects because the intracanalicular com-
ponent of the cochlear nerve, the cochlear ramus of the
internal auditory artery, and the facial nerve all traverse the
target volume.24
Another advantage of linac-based treatment is that the
treatment can be fractionated for larger tumors. A clini-
cally relevant question is whether recent advances in
treatment planning techniques can be used to further improve
linac plans. 4π radiotherapy, with optimized noncoplanar
beam orientations, has been shown to significantly reduce
normal tissue doses in the liver, prostate, brain, lung, and
head and neck.25-28 The aim of this study is to determine
whether 4π can also produce superior dosimetry for acous-
tic neuroma treatment, potentially providing better sparing
of the cochleae and reducing the risk of radiation-induced
complications such as hearing loss.
Methods and materials
Clinical plans
Thirty patients who were previously treated with radia-
tion therapy for benign acoustic neuroma were included in
this study, and their computed tomography images, plan,
dose, and contours were obtained (Table 1). Fourteen of
these patients were treated with single-fraction SRS and
prescription doses of 12 to 13 Gy. Six patients received ste-
reotactic radiation therapy (SRT) with 5 fractions of 5 Gy
each. Ten patients received intensity modulated radiation
therapy (IMRT) with 28 to 30 fractions of 1.8 Gy each. Static
beams IMRT (7-11 beams) were used for 13 patients,
dynamic conformal arcs (4-5 partial noncoplanar arcs) were
used for 11 patients, and volumetric-modulated arcs (2 full
coplanar arcs or 2-4 noncoplanar partial arcs) were used
for 6 patients.
The plans were created using the machine parameter file
for a Novalis Tx machine equipped with a 0.25 cm high-
definition, multileaf collimator. The dose calculation
resolution was 2 mm using the Analytical Anisotropic Al-
gorithm, Version 10.0.28. The treatment regimen was
determined on the basis of tumor size and achievable
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organ-at-risk (OAR) sparing. Examples of the beam ori-
entations for these plans are shown in Figure 1. The
brainstem, chiasm, cochlea (one or both, depending on the
tumor location), eyes, lenses, and optical nerves were in-
cluded as critical organs for all plans.
4π plans
4π plans were made for each patient using the optimi-
zation process previously published.25,29 The optimization
process started with a pool of 1162 candidate beams making
up the 4π solid angle space, each with a separation of 6°.
A computer-assisted design model of the Varian TrueBeam
system, along with a 3-dimensional patient model, was used
to detect any potential collisions between the gantry and
the couch or patient.
After these beams were eliminated, the dose was calcu-
lated for 5 × 5 mm2 beamlets using convolution/superposition
with a 6 MV polyenergetic kernel. Subsequently, a greedy
column generation method was used to perform an integrated
beam orientation and fluence map optimization.29
The objective function includes manually tuned parameters
for the priority and weighting of each OAR, which were set
to penalize dose to the cochlea and other nearby critical
organs while maintaining planning target volume (PTV)
coverage. A final beam count of 20 was chosen to fully exploit
the noncoplanar space while maintaining reasonable
deliverability, as shown by a prospective patient study.30
Next, using the optimized beams, fluence map optimi-
zation and dose calculation were performed again in Eclipse
with parameters that were identical to those of the clini-
cal plans, for an unbiased comparison. The planning goal
was to match the PTV coverage of the clinical plans while
reducing the dose to the cochleae and reducing or main-
taining the doses to all other OARs.
Plan comparison
The 4π and clinical plans were evaluated on the basis
of their PTV coverage and normal tissue sparing, specifically
Table 1 Patient data
Prescription
dose (Gy)
Fractions Plan type PTV volume
(cm3)
Prescription
dose (Gy)
Fractions Plan type PTV volume
(cm3)
1 12 1 DCAT 0.5 16 25 5 Static IMRT 1.07
2 12 1 Static IMRT 5.48 17 25 5 Static IMRT 2.45
3 12 1 Static IMRT 2.7 18 25 5 VMAT 8.12
4 12 1 DCAT 1.66 19 25 5 Static IMRT 0.24
5 12 1 DCAT 3.33 20 25 5 Static IMRT 0.17
6 12 1 DCAT 2.75 21 50.4 28 VMAT 6.3
7 12 1 Static IMRT 0.74 22 50.4 28 VMAT 35.81
8 12 1 DCAT 2.79 23 50.4 28 Static IMRT 17.29
9 12 1 Static IMRT 2.54 24 50.4 28 DCAT 0.35
10 12 1 DCAT 2.24 25 50.4 28 DCAT 2.42
11 12 1 Static IMRT 3.1 26 50.4 28 DCAT 0.92
12 12 1 Static IMRT 5.23 27 50.4 28 VMAT 10.87
13 12 1 DCAT 2.65 28 50.4 28 Static IMRT 2.78
14 13 1 DCAT 1.31 29 50.4 28 VMAT 13.58
15 25 5 Static IMRT 2.54 30 54 30 VMAT 23.22
DCAT, dynamic conformal arc therapy; IMRT, intensity modulated radiation therapy; PTV, planning target volume; VMAT, volumetric-modulated
arc therapy.
Figure 1 Examples of typical beam orientations for the clinical plans with 7 to 11 static beams (left), clinical plans with 2 to 5 arcs
(middle), and 4π plans with 20 static beams (right). From Table 1, these are patients #16, #4, and #1, respectively.
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of the cochleae. The mean and maximum doses for the co-
chleae and all other OARs were compared for all plans.
The volume receiving 50% of the prescription dose (V50%)
was calculated to evaluate the dose spillage for each plan.
To evaluate dose conformity, R100 (the ratio of the 100%
isodose volume to the PTV) was compared, along with the
van’t Riet conformation number, defined as:
CN V
V
V
V
T Rx
T
T Rx
Rx
= ×, , (1)
where VT is the target volume, VT,Rx is the volume of the
target receiving a dose equal to or greater than the pre-
scription dose, and VRx is the total volume receiving the
prescription dose.31 The homogeneity index was also cal-
culated as:
HI D D
DRx
= +
−( )1 2 98% % (2)
where DRx is the prescription dose and D2% and D98% are
the minimum doses to 2% and 98% of the PTV volume.32
Radiobiologic modeling was also used to predict the
tumor control probability (TCP) and normal tissue com-
plication probability (NTCP) for SNHL. The definition of
SNHL differs between studies but is typically considered
a loss of at least 10 to 20 dB in one or more frequencies.
Because hearing function has been shown to continue de-
teriorating over long follow-up times,9 the SNHL NTCP
at both 3 and 5 years posttreatment was calculated for each
plan.
The TCP was calculated using the Poisson-based model
with the parameters shown in Table 2. The cochlea effec-
tive volume (Veff) was calculated with the Kutcher-Burman
dose volume histogram reduction scheme, which esti-
mated the volume of the cochlea and, if homogenously
irradiated to the prescription dose, would result in the same
NTCP as the actual inhomogeneous dose distribution.33 This
effective volume was then used to predict the NTCP values
for the cochlea with the Lyman model,34 using the param-
eters in Table 2.
All model parameters were selected on the basis of pub-
lished clinical data on the relationship between treatment
outcomes (tumor control and complication rates) and dose
delivered to the tumor and cochleae.9-12 Because the frac-
tionation schemes varied widely among patients in this study,
all plan doses were normalized to a reference dose of 2 Gy
per fraction for radiobiologic modeling.
Dose escalation
Although excellent local control rates have been re-
ported for acoustic neuroma treated with SRS and SRT, the
control rates decrease in long-term follow up, particularly
for larger tumors.12,35 Therefore, dose escalation may be ben-
eficial if normal tissue complication rates remain low. A
dose escalation study was performed to evaluate whether
4π radiation therapy could achieve higher tumor control rates
without increasing the risk of hearing loss for patients with
acoustic neuroma. The prescription doses for each plan were
escalated until the plans achieved TCP values of 99.5%.
The NTCP values for SNHL at 3 and 5 years posttreat-
ment were calculated for the escalated dose distributions
and compared for the clinical and 4π plans.
Results
Plan comparison
The OAR doses and conformity measures for both plan
types are given in Table 3 and Figure 2. The mean co-
chlear dose was significantly reduced with 4π from 6.29
to 4.25 Gy for SRS plans, from 11.20 to 8.00 Gy for SRT
plans, and from 30.88 to 20.93 Gy for IMRT plans. The
maximum cochlear dose was also significantly reduced by
1.58 (20%), 2.2 (15%), and 7.1 Gy (18%) for SRS, SRT,
and IMRT, respectively.
In addition, there was significant sparing of the brain-
stem with 4π, which reduced the mean and maximum
doses by 18% and 7%, respectively. These reductions were
achieved with a steeper dose gradient around the target, as
illustrated by the isodose colorwash in Figure 3. The mean
and maximum doses to the chiasm were also 39% and 38%
lower, respectively, for the 4π plans than for the clinical
plans. The mean doses to the eyes, lenses, and optical nerves
were reduced by 19% to 56% on average with 4π.
The conformity measures were also slightly better for
the 4π plan. The average V50% was 0.38 cm3 lower for the
4π plans than for the clinical plans. The 4π plans were also
able to maintain similar PTV coverage despite the major
reductions in OAR doses, as illustrated in the dose volume
histogram in Figure 4. The average R100 ratio was better
for the 4π plans (1.32 vs 1.41) as well as the van’t Riet
Table 2 TCP and NTCP model parameters
Model
parametera
TCP SNHL NTCP
(3 years)
SNHL NTCP
(5 years)
α/β 2.4 Gy 2 Gy 2 Gy
TCD50 27 Gy – –
TD50 – 31.5 Gy 19.25 Gy
γ50 1.5 0.71 0.46
n – 0.83 0.83
γ50, slope of sigmoidal dose response curve at 50% tumor control
probability/normal tissue complication probability; n, volume-effect
parameter; TCD50, tumor dose to achieve 50% tumor control prob-
ability; TD50, whole organ dose resulting in 50% normal tissue
complication probability; TCP, tumor control probability; NTCP, normal
tissue complication probability; SNHL, sensorineural hearing loss.
a α/β: Ratio of the linear and quadratic terms of the organ-
specific dose response curve.
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conformation number (0.73 vs 0.69). There was also a sta-
tistically significant increase in the PTV homogeneity
index with 4π (0.93 vs 0.92). The total monitor units for
each plan were 2248 for the 4π plans, on average, and
1561 for the clinical plans.
4π consistently improved the cochlea sparing
compared with IMRT, dynamic conformal arc, and
volumetric-modulated arc therapy (VMAT) patient
subcohorts. The mean cochlea dose was reduced by 32.2%,
26.8%, and 35.1%, respectively. The maximum cochlea dose
was reduced by 19.4%, 11.3%, and 21.3%, respectively.
The results of the radiobiologic modeling study are given
in Table 4. Although the difference was statistically sig-
nificant, the TCP for the clinical plans was only 0.3% higher
Table 3 OAR doses and conformity measures for both plan types
Plan type Average OAR doses (Gy) V50% (cm3) PTV HI van’t RietCN
Brainstem Chiasm Cochleae
SRS SRT IMRT
Clinical Mean 6.61 2.12 6.29 11.20 30.88 25.23 0.92 0.69
Max 20.03 3.27 8.05 14.92 38.79
4π Mean 5.41a 1.30a 4.25a 8.00a 20.93a 24.85 0.93a 0.73
Max 18.59a 2.04 6.47a 12.72a 31.74a
CN, conformation number; HI, homogeneity index; IMRT, intensity modulated radiation therapy; max, maximum; OAR, organ at risk; SRS, ste-
reotactic radiation surgery; SRT, stereotactic radiation therapy; PTV, planning target volume; V50%, volume that received 50% of the prescription
dose.
a Statistically significant difference from the clinical plans (2-tailed t test; p < .05).
Figure 2 Mean (top) and maximum (bottom) doses to the cochlea (stereotactic radiation surgery, stereotactic radiation therapy, and
intensity modulated radiation therapy groups), brainstem, and chiasm with the 4π plans (red) and clinical plans (blue). All differences
between the 4π and clinical plans were statistically significant (2-tailed t test, 5% significance level), except for the maximum dose to
the chiasm.
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for the clinical plans than for the 4π plans. This difference
can be explained by the significantly greater hotspots within
the PTV for the clinical plans because all plans were nor-
malized for the same target coverage. The estimated TCP
is consistent with clinical reports, in which prescription doses
of at least 12 Gy for SRS and 50 Gy for IMRT yielded TCP
values of >90%.9-12 All NTCP predictions for SNHL were
significantly higher for the clinical plans than for the 4π
plans. The average NTCP was 10.0% higher for the clinical
plans at 3 years and 18.4% higher at 5 years posttreatment.
Figure 3 Dose color wash for a patient (patient #3 in Table 1) who was treated to a prescription dose of 12 Gy in a single fraction.
Structures: Planning target volume (blue), brainstem (green), and cochlea (red).
Figure 4 Dose volume histograms (solid line: clinical plan; dashed line: 4π plan) for one of the patients who underwent stereotactic
radiation surgery in this study (patient #2 in Table 1), with a prescription dose of 12 Gy.
Table 4 Results of the radiobiological modeling and dose escalation study
Plan type Average TCP Average SNHL NTCP Average escalation
factor
Escalated SNHL NTCP
3 years 5 years 3 years 5 years
Clinical 95.7 ± 0.9% 40.8 ± 5.9% 61.7 ± 10.8% 1.162 ± 0.02 43.4 ± 6.3% 64.7 ± 11.1%
4π 95.4 ± 0.9%a 30.8 ± 5.3%a 43.3 ± 11.2%a 1.166 ± 0.02a 32.6 ± 5.5%a 46.4% ± 11.3a
SNHL, sensorineural hearing loss; NTCP, normal tissue complication probability; TCP, tumor control probability.
a Statistically significant difference from the clinical plans (2-tailed t test; p < .05; 95% confidence intervals).
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Dose escalation
To achieve a TCP of 99.5%, the prescription doses had
to be escalated by a factor of approximately 1.16 on average
for both plan types. After dose escalation, the probabili-
ties of posttreatment SNHL at 3 and 5 years were once again
significantly lower for the 4π plans, by 10.8% and 18.3%,
respectively. The average NTCP for the escalated 4π plans
was 8.2% lower than the normal (nonescalated) clinical plans
at 3 years and 15.4% lower at 5 years posttreatment.
Discussion
Although normal tissue complications are a concern for
every patient receiving radiation therapy, these risks must
be weighted even more heavily for the treatment of benign
tumors such as acoustic neuroma. The majority of these pa-
tients will have an unaffected life expectancy, and any
radiation-induced side effects could have a lasting impact
on quality of life that competes with the benefits of treat-
ment. In addition, acoustic neuroma is a highly treatable
disease. Therefore, despite high treatment success rates, tech-
nologic improvements should not stop until 100% local
control is achieved because uncontrolled tumor growth may
ultimately compromise patient hearing and other neuro-
logic functions. Although excellent local control (>98%)
can be achieved with surgical resection, this treatment option
carries significant risks in addition to hearing loss. More
than 20% of surgical patients experience complications such
as facial paralysis, neurologic damage, cerebrospinal fluid
fistula, hematoma, hydrocephalus, and even death.2-4
Radiation surgery is increasingly chosen over surgery
as a noninvasive treatment option but there are still a sig-
nificant number of cases in which the treatment either fails
to control the tumor growth or the tumor eventually recurs.
Surgical resection is typically the next course of action in
these cases because further radiation therapy would exceed
normal tissue dose tolerances. In a study by Yomo et al of
repeat radiation surgery for patients with acoustic neuroma,
2 patients required as many as 3 Gamma Knife treat-
ments (with prescription doses of 12, 12, and 14 Gy) before
achieving tumor control.36 None of the patients in this study
maintained useful hearing after receiving repeat radiation
surgery. Although an initial target dose of 12 Gy was clearly
insufficient for achieving or maintaining tumor regres-
sion in these patients, the delivery of larger single-fraction
doses is typically limited by normal tissue tolerances.
When using noncoplanar conformal and dynamic arcs
on a modern linac, dose conformity that is nearly as good
as that with Gamma Knife can be achieved, without the toxic
high maximal doses.23,24 As demonstrated in this study, 4π
radiation therapy can enable statistically significant reduc-
tions in both mean and maximum normal tissue doses,
particularly to the cochlea and brainstem. As previously men-
tioned, clinical studies have found that patients who receive
<4.2 Gy single fractional doses to the cochlea experience
significantly better hearing preservation than patients who
receive a > 4.2 Gy dose.
Our study shows that for patients treated with a single
fractional SRS dose, the mean cochlear dose can be reduced
from 6.29 Gy to 4.25 Gy, allowing potentially significant
reductions in hearing loss. On the other hand, we showed
that prescription doses for the 4π plans can be escalated
to achieve 99.5% tumor control while maintaining hearing
loss probabilities below the nonescalated clinical plans. The
ability to safely escalate prescription doses would likely
reduce the incidence of tumor recurrence and the need for
subsequent tumor resection or secondary radiation, both of
which carry major risks of hearing loss or other
complications.
In this study, heterogeneous planning techniques
including conformal arc, IMRT, and VMAT were used clini-
cally, mainly depending on the size of the tumor. Conformal
arcs were mainly used on smaller tumors, and larger tumors
benefit from the better dose homogeneity and conformity
that is achieved with intensity modulation in IMRT and
VMAT. Nevertheless, 4π radiation therapy resulted in con-
sistently improved cochlea sparing in individual planning
technique comparisons.
In this study, the noncoplanar beams were not actually
delivered. In a separate prospective clinical study,30 a similar
number of beams was delivered to patients with brain
tumors. In this study, the beams were ordered on the basis
of their couch rotation angles. That way, the treatment could
be delivered in a single couch sweep while the gantry rotated
back and forth under the guidance of pretreatment
modeling.37 With remote manual machine operation, the
treatment delivery time was less than 35 minutes. In the
phantom test using fully automated machine control that
has not been approved for patients, the same treatment could
be delivered in less than 15 minutes. We expect similar treat-
ment time for patients with acoustic neuroma.
Conclusions
4π radiotherapy achieves significantly greater normal
tissue sparing compared with radiation therapy tech-
niques that are typically used in acoustic neuroma treatment.
These major reductions in cochlear dose may reduce the
risk of normal tissue complications such as hearing loss and
enable the safe escalation of prescription doses to poten-
tially improve tumor control rates.
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